



Health Care Worldwide



Conference Call May 6, 2004

Agenda

I. Business Update

- Fresenius Group
- Fresenius Kabi
- Fresenius ProServe
- Fresenius Biotech

II. Fresenius Group – 2004 Priorities

III. Fresenius Financials Q1/2004

IV. Outlook

Fresenius Group: Excellent start into 2004

Q1/2004	Sales 1,720 €m	EBIT 197 €m	EAT 39 €m
Growth at constant currency rates	+ 8 %	+ 12 %	+ 17 %
Growth at actual currency rates	- 1 %	+ 2 %	+ 8 %

- Impressive earnings performance of Fresenius Medical Care and Fresenius Kabi
- Significant currency translation impact
- Fully in line with 2004 projections

Business Segments: Key Issues Q1/2004

	Fresenius Medical Care	Fresenius Kabi	Fresenius ProServe
Sales Growth	1,459 \$m + 12 %	362 €m + 2 %	199 €m + 20 %
EBIT Growth	198 \$m + 17 %	41 €m + 17 %	1 €m - 83 %

- Fresenius Medical Care - Excellent top-line growth across all regions
- Net income up 30 % from Q1/2003
- Fresenius Kabi - Strong 6 % organic revenue growth
- Continued margin improvement
- Fresenius ProServe - Operational performance impacted by low bed utilization rate and reduced investment activities of the Pharma industry
- Ongoing process improvement


Fresenius Kabi: Key Figures Q1/2004

€m	Q1/2004	Q1/2003	Change
Sales	362	355	+ 2 %
Hospital Business	298	284	+ 5 %
Ambulatory Care Business	64	71	- 10 %
adjusted for divestiture			- 4 %
EBITDA	58	54	+ 7 %
EBITDA margin	16.0 %	15.2 %	
EBIT	41	35	+ 17 %
EBIT margin	11.3 %	9.9 %	

Fresenius Kabi: Revenue Growth and Distribution


Strong organic growth

Q1/2004
Growth yoy (in%)



Organic growth Currency translation effects Divestitures Total growth

Revenue distribution and growth by region






Q1/2004: 362 €m

Fresenius ProServe: Key Figures Q1/2004

€m	Q1/2004	Q1/2003	Change
Sales	199	166	+ 20 %
Healthcare Business	179	140	+ 28 %
- Service	122	116	+ 5 %
- Projects	57	24	+ 138 %
Pharma Industry Business	20	26	- 23 %
EBITDA	8	12	- 33 %
EBITDA margin	4.0 %	7.2 %	
EBIT before one-time expenses	2	6	- 67 %
EBIT margin	1.0 %	3.6 %	
EBIT after one-time expenses	1	6	- 83 %
EBIT margin	0.5 %	3.6 %	

Fresenius Biotech

Accomplished:

- Manufacturing license to produce genetically modified T-cells for HIV therapy received 
- Orphan Drug Designation for the antibody removab[®] to treat patients with ovarian cancer received 
- A Phase IIa study for the treatment of ovarian cancer starting up 

To follow in 2004:

- HIV proof of principle go/no go
- NSCLC final report phase I study
- Breast cancer final report phase I study
- Peritoneal CA final report phase I study

Fresenius Group – 2004 Priorities

Fresenius Medical Care

- Focus on same-store treatment and revenue per treatment growth
- Fully capture benefits of single-use strategy

Fresenius Kabi

- Strategic add-on acquisitions in emerging markets
- Continued margin improvement due to plant optimization and improved sourcing

Fresenius ProServe

- Finalize profit improvement program by the end of 2004

Fresenius Biotech

- Achieve 2004 clinical study milestones

Fresenius

Financials Q1/2004

Fresenius Group: Financial Achievements Q1/2004


- Strong currency-adjusted sales growth of 8 % and organic growth of 6 %
- Remarkable net income growth of 8 %; currency-adjusted: 17 %
- Strong Free Cashflow (after acquisitions and dividends) of 98 €m (+ 72 %)
- Debt / EBITDA ratio of 2.7

Fresenius Group: Key Figures

		Q1/2004	Q1/2003	Change actual rates	Change constant rates
Sales	€m	1,720	1,729	- 1 %	+ 8 %
EBITDA	€m	269	271	- 1 %	+ 8 %
EBIT	€m	197	194	+ 2 %	+ 12 %
Interest result	€m	- 52	- 64	+ 19 %	+ 11 %
Taxes	€m	- 58	- 51	- 14 %	- 25 %
Minority interest	€m	- 48	- 43	- 12 %	- 26 %
Net income	€m	39	36	+ 8 %	+ 17 %
EPS ordinary share	€m	0.94	0.87	+ 8 %	+ 17 %
EPS preference share	€m	0.95	0.88	+ 8 %	+ 17 %

Fresenius Group: Sales Analysis Q1/2004


Sales Growth




- Organic growth + 6 %
- Acquisitions contributing + 2 %
- Strong currency impact of - 9 %

Fresenius Group: Capital Expenditure and Acquisitions

Capex + acquisitions




Regional distribution



Fresenius Group: Cash Flow Statement


Strong cash flow performance



- Operating CF: + 33 %
- FCF (after acquisitions and dividends): + 72 %
- Positive development in working capital

Q1/2004

Fresenius Group: Solid Balance Sheet Structure



Fresenius Group: Debt and Debt Ratios

€m	31.3.2004	31.12.2003
Debt*	3,155	3,148
Net debt	3,003	3,023
Net debt/EBITDA	2.7	2.7

* incl. A/R liabilities

Fresenius Group: 2004 Outlook Confirmed

Revenue growth at constant currency	Mid-single digit
Net income growth rate at constant currency	25 – 30 %
Capital expenditure	~ 300 €m
Acquisitions	~ 120 €m

Fresenius

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.